GW Pharma soars following positive results for lead drug

The price of GW Pharmaceuticals Plc rose by 41.8% in London following the UK company’s announcement of positive Phase 3 results for its lead drug, Sativex, a cannabinoid compound for treating multiple sclerosis (MS).